BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in ...

Gilead is well-positioned to maintain its leadership in the ... Separately, we're pleased FDA has granted Kite the ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Mind Medicine (MNMD – Research Report) yesterday and set a price target of ...

Cambridge, MA, October 28, 2024 –Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...